To further investigate whether integrin β3 could regulate AXL expression in EGFR-TKI resistant cells, integrin β3 was knocked down in erlotinib-resistant NSCLC cell lines, which subsequently led to a significant reduction of AXL expression as well as a decreased resistance to erlotinib. This evidence concerns the gene AXL and non-small cell lung carcinoma.